By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MabVax Therapeutics, Inc. 

11588 Sorrento Valley Road
Suite 20
San Diego  California  92121  U.S.A
Phone: 858-259-9405 Fax:



Company News
MabVax Therapeutics Announces Pricing Of Registered Direct Offering 8/14/2017 6:49:05 AM
MabVax Therapeutics Board Of Directors Authorizes The Company To Explore Strategic Alternatives 7/24/2017 7:54:36 AM
MabVax Therapeutics Commences Patient Dosing In MVT-1075 Radioimmunotherapy Phase I Clinical Trial For The Treatment Of Pancreatic, Colon And Lung Cancers 6/27/2017 8:04:25 AM
MabVax Therapeutics Reports Positive Phase I Results For MVT-2163 ImmunoPET Imaging Agent 6/14/2017 6:29:52 AM
MabVax Therapeutics Phase I Trial Results Of Antibody Therapy MVT-5873 For The Treatment Of Advanced Pancreatic Cancer Presented At The 2017 ASCO Annual Meeting 6/5/2017 6:43:26 AM
MabVax Therapeutics Signs Research Agreement With Memorial Sloan-Kettering Cancer Center To Develop Novel CAR T-Cell Based Anti-Cancer Immunotherapies For Treatment Of Pancreatic And Small Cell Lung Cancers 5/31/2017 6:22:43 AM
MabVax Therapeutics Reports First Quarter 2017 Operational And Financial Results 5/24/2017 9:00:01 AM
MabVax Therapeutics Announces The Closing Of Its $4.1 Million Public Offering 5/22/2017 7:00:53 AM
MabVax Therapeutics Announces $4.1 Million Public Offering 5/16/2017 9:42:43 AM
MabVax Therapeutics Presents Two Posters At The AACR Annual Meeting On A Novel Radioimmunotherapy Treatment For Pancreatic Cancer 4/5/2017 7:57:47 AM